We describe a routine method for determining plasma concentrations of qulnidine by liquid chromatography. The procedure requires 1.0 ml of plasma (or serum) and involves Internal standard addition, extraction with ether, and separation on a column of microparticulate silica. Dayto-day CV (15 days) was <5% and no deterioration in column performance has been observed during 12 months. Comparison with a fluorometric procedure gave a correlation coefficient of 0.995.
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Quinidine is an effective and widely used antiarrhythmic agent (1) . Individual patients' differences in absorption, distribution, and elimination of the drug, along with a frequent onset of toxic symptoms when concentrations in plasma exceed the therapeutic range, make it desirable to monitor the plasma concentration of quinidine. The therapeutic range for quinidine is generally accepted to be 3 to 6 mg/liter (2) . Its toxic reactions include nausea, vomiting, diarrhea, and, more seriously, arrhythmias or sudden death (3) . Plasma concentrations, until recently, were commonly determined by a fluorescence method (4-6), although Hoffman et al. (7) used a gas-liquid chromatographic procedure.
In the past few years high-performance liquid chromatography has proved to be extremely useful in analysis for various drugs in serum or plasma. Several workers (8-11) have described liquid-chromatographic procedures for the assay of quinidine (and metabolites) in serum samples. In all these methods a reverse-phase column is used and in those of Conrad et al. This report describes a rapid, accurate, and specific highperformance liquid-chromatographic determination of quinidine, with use of a Partisil (1O-m silica) column. We used l-cinchonidine as the internal standard. The chromatographic conditions used separated quinidine and dihydroquinidine, a contaminant in quinidine products that report- edly has greater antiarrhythniic activity and toxicity than does quinidine itself (8).
Materials and Methods

Apparatus
A Model 3500 liquid chromatograph with an SP8200 ultraviolet detector set at 280 nm (both from Spectra-Physics, Santa Clara, Calif. 95051) was used. The 25 cm X 4.6 mm X 6.4 mm column was prepared with "Partisil-lO" (ReeveAngel).
The eluent was a modification of one described by Jane (12) and consisted of methanol:1 mol/liter ammonium nitrate:2 mol/liter ammonium hydroxide (27/2/1 by vol). The solvent was degassed and filtered before use. Column operating conditions were 1.2 ml/min flow rate at 345 MPa (500 psi) and room temperature.
Reagents
Quinidine sulfate dihydrate and l-cinchonidine were obtained from Aldrich Chemical Co., Inc., Milwaukee, Wis. 53223.
Methanol and diethyl ether were purchased from Burdick and Jackson Laboratories, Inc., Muskegon, Mich. 49422. Ammonium nitrate and sodium borate decahydrate were obtained from J. T. Baker Chemical Co., Phillipsburg, N.J. 08865.
Ammonium hydroxide (approximately 58%) was purchased from Mallinckrodt, Inc., St. Louis, Mo. 63147.
Standards
Quinidmne standards, 2, 5, and 10 mg/liter, were made up as required, in blood-bank plasma.
A methanolic solution of l.cinchonidine (50 mg/liter) was prepared as needed.
Procedure
To 1 ml of plasma, add 50 Mlof the cinchonidine internal standard solution, 2 ml of borate buffer (pH 9.0, saturated sodium borate), and 6 ml of diethyl ether. Vortex-mix the mixture for about 30 s, centrifuge, and transfer the ether to an evaporation tube. After evaporation under a stream of air 
Results and Discussion
It was found that a microparticulate silica column gave an efficient separation of quinidine and dihydroquinidine. Lagerstrom et al. (13) also used a silica column to monitor several antiarrhythmic drugs, including quinidine, in plasma. However, these workers do not indicate whether they could separate quinidine and its dihydro derivative.
Representative chromatograms by our procedure are shown in Figure 1 . With drug-free plasma taken through the described procedure, no interfering peaks were observed.
The column eluent is monitored routinely at 280 nm. At the pH of the eluting solvent quinidine has approximately equal absorptions at 280 and 254 nm, the filters commonly used in fixed-wavelength detectors. Detection at 280 nm was chosen because of the possibility of more interference by spurious compounds when the eluting solvent is monitored at 254 nm.
Peak height ratios of the drug to internal standard were used as the basis for quantitation.
To determine linearity, we injected plasma-based standards of 2, 5, and 10 mg of quinidine per liter. Although the quinidine peak and that for the internal standard are incompletely separated, the peak height ratios were linear over the range studied. Within-run precision and analytical recoveries were determined for various plasma concentrations of quinidine (Table 1 ). In addition, we assessed day-to-day precision of the assay by analysis of a plasma sample containing 3 mg of quinidine per liter ( Table 1) .
Interference by other drugs was investigated; caffeine, theophylline, lidocaine, the commonly used anticonvulsants, and the commonly used benzodiazepine drugs did not inter- However, the therapeutic range for this drug plus its normetabolite is reportedly 95-200 ,ig/liter,1 a concentration that would not interfere with the determination of quinidine.
Of the other commonly prescribed antiarrhythmic agents N-acetyl procainamide (the major metabolite of procainamide) has a retention time similar to that for l-cinchonidine. This interference could be overcome either by using 330 nm (9) as the detection wavelength or by using another internal standard.
Under the described chromatographic conditions, quinine is not separated from quinidine. In a recent study (14), In addition to good day-to-day reproducibility ( 
